 Overweight
"Overweight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A status with BODY WEIGHT that is above certain standard of acceptable or desirable weight. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal "over fat".
| Descriptor ID |
D050177
|
| MeSH Number(s) |
C23.888.144.699 E01.370.600.115.100.160.120.699 G07.100.100.160.120.699
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Overweight".
Below are MeSH descriptors whose meaning is more specific than "Overweight".
This graph shows the total number of publications written about "Overweight" by people in this website by year, and whether "Overweight" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 | | 2006 | 2 | 4 | 6 | | 2007 | 6 | 4 | 10 | | 2008 | 8 | 7 | 15 | | 2009 | 10 | 2 | 12 | | 2010 | 7 | 12 | 19 | | 2011 | 11 | 5 | 16 | | 2012 | 8 | 9 | 17 | | 2013 | 10 | 11 | 21 | | 2014 | 20 | 8 | 28 | | 2015 | 21 | 8 | 29 | | 2016 | 8 | 11 | 19 | | 2017 | 18 | 5 | 23 | | 2018 | 9 | 14 | 23 | | 2019 | 17 | 9 | 26 | | 2020 | 7 | 6 | 13 | | 2021 | 6 | 13 | 19 | | 2022 | 7 | 21 | 28 | | 2023 | 5 | 15 | 20 | | 2024 | 8 | 5 | 13 | | 2025 | 14 | 4 | 18 | | 2026 | 6 | 1 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Overweight" by people in Profiles.
-
Oselinsky KM, Hill EB, Ostendorf DM, Pan Z, Bing K, Wayland LT, Simpson C, Clark KC, Sandoval A, Thomas EA, Marker RJ, Kabos P, MacLean PS, Catenacci VA. Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. JMIR Res Protoc. 2026 Jul 23; 15:e86281.
-
Yeo EN, Scadden AW, Caterer ZT, Sutton KJ, Konigsberg IR, Cole JB, Litkowski EM, Pan Z, Lozupone CA, Ostendorf DM, MacLean PS, Melanson EL, Bessesen DH, Borengasser SJ, Lange EM, Catenacci VA, Stanislawski MA. Multi-omic modelling of body mass index response to a dietary weight loss intervention. Gut Microbes. 2026 Dec 31; 18(1):2696645.
-
Leonhard AG, Josey K, Castaneda JM, Chee M, Duan KI, Nadeem H, Plumley R, Triplette M, Smith NL, Au DH, Feemster LC, Donovan LM. Receipt of glucagon-like peptide-1 receptor agonists among rural patients with obstructive sleep apnea and excess weight. Ann Am Thorac Soc. 2026 Jul 01; 23(7):1087-1096.
-
Beals JW, Smith GI, Farabi SS, Patterson BW, Lucey BP, Broussard JL, Wright KP, Klein S. Sleep Extension Improves Sleep Health but Not Insulin Sensitivity in People With Overweight or Obesity Who Maintain Habitual Short Sleep Schedules. Diabetes Care. 2026 May 01; 49(5):740-745.
-
Birznieks CL, Wang W, Steele C, You Z, Gitomer B, Chonchol M, Nowak KL. Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease. Kidney Blood Press Res. 2026; 51(1):218-224.
-
Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
-
Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
-
Creasy SA, Oselinsky KM, Willis EA, Caldwell AE, Rosenberg R, Ostendorf DM, Panter S, Wayland L, Bing K, Lorentzen J, Breit M, Clark K, Sandoval A, Donnelly JE, Melanson EL, Catenacci VA. Comparison of morning vs evening exercise on weight loss and related health behaviors in individuals with overweight or obesity: study protocol for a 56-week randomized controlled trial (TIMEX). Trials. 2025 Dec 12; 27(1):45.
-
Constantine E, Enthoven L, Kahan R, Pflug EM, Lauder A. The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients. J Am Acad Orthop Surg. 2026 Jun 15; 34(12):e1610-e1619.
-
Park S, Englund EK, Fujiwara T, Enge D, Schäfer M, Gerstner Saucedo J, Clark EW, Abushamat LA, Scalzo RL, Fonseca B, Hunter KS, Sammel MD, Regensteiner JG, Reusch JEB, Barker AJ. Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus. Cardiovasc Diabetol. 2025 Dec 08; 25(1):7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|